Large list of disease areas suitable for cheminformatics-driven discovery

Now, your ‚Äúwide and deep‚Äù list. These are areas where small molecules, fragments, or PROTAC-like modalities can play a role and where cheminformatics is highly relevant.

I‚Äôll group them by domain; each bullet is something Lika could eventually target with specialized pipelines and oracles.

üß† CNS & Neurology

Alzheimer‚Äôs disease

Parkinson‚Äôs disease

Huntington‚Äôs disease

Amyotrophic lateral sclerosis (ALS)

Multiple sclerosis (MS)

Epilepsy (various subtypes)

Migraine (incl. CGRP-targeted therapies)

Neuropathic pain (diabetic neuropathy, postherpetic neuralgia)

Depression (major depressive disorder)

Bipolar disorder

Schizophrenia and related psychoses

Anxiety disorders (GAD, panic)

Insomnia and sleep disorders

ADHD

Autism spectrum‚Äìrelated symptom modulation (not cure but symptom targets)

Spinal muscular atrophy (small-molecule splicing modulators / pathway modulators)

Myasthenia gravis (symptomatic and immune-targeting small molecules)

Rare channelopathies (e.g., Dravet syndrome, other sodium/calcium channel diseases)

ü¶† Infectious Diseases ‚Äì Viral

HIV/AIDS (entry inhibitors, integrase inhibitors, maturation inhibitors)

Hepatitis B

Hepatitis C (NS3/4A, NS5A, NS5B already classic‚Äîstill space for new analogs)

Influenza (neuraminidase, polymerase, host-target modulators)

SARS-CoV-2 and other coronaviruses (protease, polymerase, host proteases)

Respiratory syncytial virus (RSV)

Cytomegalovirus (CMV)

Herpes simplex virus (HSV-1, HSV-2)

Varicella zoster virus

Human papillomavirus (HPV; pathway modulators, not direct virus block)

Emerging viral threats (Dengue, Zika, Chikungunya) ‚Äì host or viral target small molecules

üß´ Infectious Diseases ‚Äì Bacterial (including AMR focus)

Tuberculosis (TB) ‚Äì multiple enzyme & cell-wall targets

Non-tuberculous mycobacteria

MRSA and other resistant Staphylococcus aureus

VRE (vancomycin-resistant Enterococci)

Carbapenem-resistant Enterobacteriaceae

Pseudomonas aeruginosa (multi-drug resistant strains)

Clostridioides difficile

Helicobacter pylori

Gonorrhea (multi-drug resistant Neisseria gonorrhoeae)

Syphilis (Treponema pallidum) ‚Äì less small molecule innovation but still a space

Novel broad-spectrum or narrow-spectrum antibacterials for specific enzymes, efflux pumps, quorum sensing

üçÑ Infectious Diseases ‚Äì Fungal & Parasitic

Candida spp. (including C. auris)

Aspergillus spp.

Cryptococcus

Dermatophyte infections (onychomycosis, tinea)

Malaria (Plasmodium falciparum & vivax)

Leishmaniasis

Chagas disease (Trypanosoma cruzi)

African sleeping sickness (T. brucei)

Toxoplasmosis

Helminth infections (various anthelmintic targets)

üß¨ Oncology (massive small-molecule space)

Solid tumors & general targets:

Non-small cell lung cancer (EGFR, ALK, ROS1, MET, RET, KRAS, etc.)

Small cell lung cancer

Breast cancer (ER+, HER2+, triple-negative subtypes)

Prostate cancer (androgen receptor, PARP, etc.)

Ovarian cancer

Colorectal cancer (KRAS, BRAF, EGFR, etc.)

Pancreatic cancer

Gastric cancer

Hepatocellular carcinoma (HCC)

Renal cell carcinoma

Melanoma (BRAF, MEK, etc.)

Thyroid cancers

Hematologic malignancies:

Chronic myeloid leukemia (CML ‚Äì BCR-ABL)

Acute myeloid leukemia (AML ‚Äì FLT3, IDH, etc.)

ALL (acute lymphoblastic leukemia)

Multiple myeloma

Non-Hodgkin lymphoma (BTK, PI3K, etc.)

Hodgkin lymphoma

Mechanistic niches (great for cheminformatics):

Kinase inhibitor discovery across many kinases

HDAC and epigenetic modulators

Bromodomain (BET) inhibitors

Proteasome inhibitors

DNA damage repair (PARP, ATR, CHK1, etc.)

Metabolic enzyme inhibitors (IDH1/2, others)

PROTAC-style degraders for various oncoproteins (E3 ligase binders + warheads)

‚ù§Ô∏è Cardiometabolic & Renal

Hypertension (multiple receptor/enzyme targets)

Heart failure (various neurohormonal and metabolic modulators)

Atherosclerosis and dyslipidemia (PCSK9, CETP, Lp(a) & novel targets)

Thrombosis and anticoagulation (FXa, thrombin, new coagulation targets)

Type 2 diabetes (DPP-4, SGLT2, GLP-1 oral small molecules, GIP/dual modulators)

Obesity (small molecules complementing peptides, central appetite targets, etc.)

Non-alcoholic fatty liver disease (NAFLD) / NASH

Diabetic nephropathy

Chronic kidney disease (CKD) ‚Äì various pathways (RAAS, metabolic)

Gout (urate transporters and related enzymes)

üî• Autoimmune & Inflammatory

Rheumatoid arthritis

Psoriatic arthritis

Ankylosing spondylitis / axial spondyloarthritis

Systemic lupus erythematosus (SLE)

Inflammatory bowel disease (Crohn‚Äôs, ulcerative colitis)

Psoriasis (beyond biologics ‚Äì small molecule JAK/SYK/TYK2, etc.)

Atopic dermatitis (small molecule JAK inhibitors, etc.)

Multiple sclerosis (oral agents like S1P modulators and beyond)

Vasculitides (e.g., ANCA-associated) ‚Äì small molecule immunomodulators

Gouty arthritis (inflammation cascade)

Cheminformatics here is great for:

JAK/SYK inhibitors

S1P modulators

BTK, TYK2, PI3K, etc.

ü´Å Respiratory

Asthma (including severe eosinophilic asthma ‚Äì small molecules alongside biologics)

COPD

Pulmonary hypertension (multiple pathways)

Cystic fibrosis (CFTR modulators ‚Äì classic cheminformatics success story)

Idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases

üß™ Endocrine & Metabolic (beyond diabetes)

Thyroid diseases (hyper/hypothyroidism control)

Cushing‚Äôs syndrome (adrenal steroidogenesis inhibitors)

Hyperaldosteronism

Hypogonadism / hormone modulation (selective receptor modulators)

Osteoporosis (bone resorption/formation modulators)

Rare inborn errors of metabolism where small molecules modulate enzymes or chaperone misfolded proteins (e.g., PKU analogs, urea cycle disorders, lysosomal storage diseases where chaperones apply)

üß† Rare Genetic / Orphan Diseases (cheminformatics angles)

Cystic fibrosis (already noted, but huge)

Spinal muscular atrophy (small-molecule splicing enhancers / pathway modulators)

Duchenne muscular dystrophy (UTR / splicing / downstream pathways)

Sickle cell disease (HbS polymerization inhibitors, modulators of HbF, etc.)

Thalassemias (HbF regulation, iron metabolism)

Gaucher disease (substrate reduction therapy)

Fabry disease (chaperones, substrate reduction)

Pompe disease (adjunct small molecules)

PKU (phenylalanine hydroxylase modulators / cofactor analogs)

Various channelopathies (Nav, Cav, Kv channels in rare epilepsy / cardiac arrhythmias)

Rare oncogenic drivers where small dedicated inhibitors can be designed

üßª Gastrointestinal & Hepatic

GERD and acid-related disorders (beyond PPIs)

Peptic ulcer disease (H. pylori-related + mucosal protection)

IBS (IBS-C, IBS-D symptom modulators)

IBD (already under autoimmune, but small molecules for integrins, sphingosine pathways, etc.)

Cholestatic liver diseases (PBC, PSC ‚Äì bile acid modulators, FXR agonists)

NAFLD/NASH (again ‚Äì multi-pathway metabolic and inflammatory targets)

üßç‚Äç‚ôÄÔ∏è Women‚Äôs Health / Urogenital

Endometriosis

Uterine fibroids

Polycystic ovary syndrome (PCOS)

Contraception (novel hormone and non-hormone small molecules)

Menopause symptoms (non-hormonal small molecules)

Overactive bladder

Interstitial cystitis / bladder pain syndrome

Benign prostatic hyperplasia (BPH)

üß© Neuromuscular & Pain

Chronic lower back pain (central & peripheral targets)

Fibromyalgia (central sensitization modulators)

Osteoarthritis pain (NGF, ion channels, etc.)

Peripheral neuropathy (already under CNS)

üßø Ophthalmology

Glaucoma

Age-related macular degeneration (adjunct small molecules)

Diabetic retinopathy

Dry eye disease

Uveitis (inflammatory targets)

üíä Adjacent Modalities Where Cheminformatics Still Helps

Even when final therapies are biologics or gene therapies, cheminformatics can target:

Small-molecule modulators that:

Improve delivery

Modulate immune responses

Enhance or complement gene therapies / RNA therapies

PROTACs and molecular glues for:

Neurodegeneration targets

Oncology targets

Immune targets